Pharmacotherapy
CASE STUDY for Cardiovascular Disorders
1 :PHAMACOTHERAPY CARDIOVASCULAR
DISORDER Case Study Selected: Case Study 1
Patient CB has a history of strokes. The patient has been diagnosed with type 2 diabetes,
hypertension, and hyperlipidemia. Drugs currently prescribed include the following:
Glipizide 10 mg po daily
HCTZ 25 mg daily
Atenolol 25 mg po daily
Hydralazine 25 mg qid
Simvastatin 80 mg daily
Verapamil 180 mg CD daily
Factor Influencing the Pharmacokinetic and Pharmacodynamics Process: Behavior
Adulthood is accompanied by a considerable measure of hindrance and reduction in the
usefulness of all frameworks that offer support between cells and organs (Culebras, 2013). Due
to aging, it is difficult to maintain homeostatic function, which lowers the ability to adapt to
outside anxieties. This paper analyzes how age would influence pharmacokinetic and
pharmacodynamics in the patient CB that has a history of strokes.
Because of aging and the organs cannot work adequately; the body find it hard to handle drugs
and accordingly, the quantity of pharmaceuticals in the body will increase disease complications.
Among 834 hypertension patients with an earlier stroke attack, 87% had a normal age of 71
years, and 56% had hypertension while 64% were men, (Krantz, Baum, Singer, and Singer,
2013). Ibuprofen 81 mg daily is the least dose given to individuals with stroke. Nonetheless, this
would not be good for aging individuals. It might lead to a considerable measure of reaction and
even inward draining as a result of the vulnerability to type 2 diabetes since headache medicine
cannot function admirably when the body is battling another disease.
Aging individuals have no intestinal mucosal surface, which contributes to diminishing
gastrointestinal blood stream and gastric acidity (Culebras, 2013). Consequently ingestion,
transportation, and disposal of the capsules drugs, for example, Verapamil 180mg and Atenolol
25 mg, will take more time to achieve the poisonous level or drop out to sub-remedial levels
because of low lipid dissolvability (Frishman, 2012). To enhance the patient's medication
treatment plan, patients ought to begin with a lesser dosage, and stay away from unexpected
This study source was downloaded by 100000842568006 from CourseHero.com on 03-26-2022 18:33:12 GMT -05:00
https://www.coursehero.com/file/21859402/6521-week-3-Pharmacotherapy-for-Cardiovascular-Disorders/
CASE STUDY for Cardiovascular Disorders
1 :PHAMACOTHERAPY CARDIOVASCULAR
DISORDER Case Study Selected: Case Study 1
Patient CB has a history of strokes. The patient has been diagnosed with type 2 diabetes,
hypertension, and hyperlipidemia. Drugs currently prescribed include the following:
Glipizide 10 mg po daily
HCTZ 25 mg daily
Atenolol 25 mg po daily
Hydralazine 25 mg qid
Simvastatin 80 mg daily
Verapamil 180 mg CD daily
Factor Influencing the Pharmacokinetic and Pharmacodynamics Process: Behavior
Adulthood is accompanied by a considerable measure of hindrance and reduction in the
usefulness of all frameworks that offer support between cells and organs (Culebras, 2013). Due
to aging, it is difficult to maintain homeostatic function, which lowers the ability to adapt to
outside anxieties. This paper analyzes how age would influence pharmacokinetic and
pharmacodynamics in the patient CB that has a history of strokes.
Because of aging and the organs cannot work adequately; the body find it hard to handle drugs
and accordingly, the quantity of pharmaceuticals in the body will increase disease complications.
Among 834 hypertension patients with an earlier stroke attack, 87% had a normal age of 71
years, and 56% had hypertension while 64% were men, (Krantz, Baum, Singer, and Singer,
2013). Ibuprofen 81 mg daily is the least dose given to individuals with stroke. Nonetheless, this
would not be good for aging individuals. It might lead to a considerable measure of reaction and
even inward draining as a result of the vulnerability to type 2 diabetes since headache medicine
cannot function admirably when the body is battling another disease.
Aging individuals have no intestinal mucosal surface, which contributes to diminishing
gastrointestinal blood stream and gastric acidity (Culebras, 2013). Consequently ingestion,
transportation, and disposal of the capsules drugs, for example, Verapamil 180mg and Atenolol
25 mg, will take more time to achieve the poisonous level or drop out to sub-remedial levels
because of low lipid dissolvability (Frishman, 2012). To enhance the patient's medication
treatment plan, patients ought to begin with a lesser dosage, and stay away from unexpected
This study source was downloaded by 100000842568006 from CourseHero.com on 03-26-2022 18:33:12 GMT -05:00
https://www.coursehero.com/file/21859402/6521-week-3-Pharmacotherapy-for-Cardiovascular-Disorders/
